Lallemand Pharma AG
Survey of Incidence of Respiratory Tract Infections
- Conditions
- Healthy AdultsNot Healthy Adults
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 2750
- Registration Number
- NCT06649032
- Locations
- 🇮🇹
Dr F Pugliese, Bari, Italy
🇮🇹Università degli Studi di Cagliari, Cagliari, Italy
🇮🇹Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
Prevention With Healsea in Adults Against Respiratory Infection Study
- Conditions
- Healthy Subjects (HS)
- Interventions
- Device: Healsea Children nasal spray
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 198
- Registration Number
- NCT06613906
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex EOOD,, Sofia, Bulgaria
HEALSea Nasal Spray for Prevention of Infections in Children
- Conditions
- Healthy Subjects
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 138
- Registration Number
- NCT06582589
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment Sveti Ivan Rilski -2003 OOD, Dupnitsa, Bulgaria
🇧🇬Medical Center Plovdimed Ltd, Plovdiv, Bulgaria
🇧🇬Medical Center Iskar EOOD, Sofia, Bulgaria
BАbykids Spray In Common Cold
- Conditions
- Common ColdRhinitis Viral
- Interventions
- Device: PlaceboDevice: Healsea Babykids
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 200
- Registration Number
- NCT05819203
- Locations
- 🇧🇬
Medical center, Vratsa, Bulgaria
Testing the Efficacy in Adults With Cold of HEalsea Rescue*
- Conditions
- Common Cold
- Interventions
- Device: PlaceboDevice: Healsea Rescue*
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 200
- Registration Number
- NCT05819190
- Locations
- 🇧🇬
DCC Convex Ltd., Sofia, Bulgaria
Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
- Conditions
- Common ColdAllergy
- Interventions
- Device: Healsea® ChildrenOther: Conventional therapies for common cold
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 186
- Registration Number
- NCT05034328
- Locations
- 🇵🇱
Research Site, Łomża, Poland
Impact of Symbiofilm On Nasal Microbiota
- Conditions
- Rhinosinusitis ChronicMicrobiome
- Interventions
- Device: Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 12
- Registration Number
- NCT05015530
- Locations
- 🇫🇷
Larrey Hospital, Toulouse, France
Efficacy Of Bacterial Lysate In Asthmatic Children
- Conditions
- Allergic Asthma
- Interventions
- Biological: PLACEBOBiological: ISMIGEN
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 150
- Registration Number
- NCT02541331
- Locations
- 🇵🇱
LASERMED Diagnosis and Treatment Centre, Chelm, Poland
🇵🇱Children University Hospital - Pneumology and Rheumatology Dept, Lublin, Poland
🇵🇱Medical Centre Lucyna and Andrzej Dymek, Zawadzkie, Poland
Advanced Immunological Approach in COPD Exacerbation
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Biological: IsmigenBiological: Placebo
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Lallemand Pharma AG
- Target Recruit Count
- 288
- Registration Number
- NCT02417649
- Locations
- 🇮🇹
Respiratory Physiopatology Unit, Mellino Mellini hospital, Chiari, Italy
🇮🇹Pneumology Department - San Paolo Hospital, Milan, Italy
🇮🇹Pneumology Unit, San Gerardo hospital, Monza, Italy